The company develops and clinically tests a novel nutraceutical/medical food that offers a dietary preventive therapy for higher-frequency migraines and other related neurological diseases characterized by metabolic dysfunction. The food contains a lead product's active substance, which is an endogenous metabolite - a Ketone body, that can be used by the human brain as an alternative source of fuel to glucose when glucose utilization or transport is compromised. KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it benefits from being part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs, and a world-leading biotech-startup-ecosystem.